Adherence to recombinant human growth hormone (r-hGH) therapy is essential for achieving optimal growth outcomes. This retrospective post-market clinical follow-up analysis compared adherence outcomes from real-world device logs of Easypod® 3 (EP3) and Easypod® 2 (EP2). At 12 months, mean adherence was 92.5% (EP3) and 92.4% (EP2), with more than 85% patients maintaining acceptable threshold adherence. These findings support the reliability of device-recorded adherence data and highlight the value of connected injection devices for monitoring adherence with r-hGH therapy and facilitating patient engagement.